secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001193125-22-001706
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam promotes Dr. Akshay Vaishnaw to President; continues scientific leadership
--------------------------------------------------------------------------------

- Dr. Vaishnaw appointed President effective Jan 1, 2022; previously President of R&D.
- Receives $725,000 base salary, 60% target bonus, and $2M stock option grant vesting over 4 years.
- Yvonne Greenstreet named CEO effective same date; Vaishnaw to lead sustainable innovation in R&D.
- Vaishnaw has been at Alnylam since 2006; also serves on boards of Editas Medicine and Scholar Rock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/0001193125-22-001706-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312522001706/d251998d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-001706

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer